| Name | Title | Contact Details |
|---|
Quantapore`s novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases.
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.
ILiAD Biotechnologies, LLC manufactures vaccines for the prevention and treatment of disease caused by Bordetella Pertussis.
NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.